Migraine pharmacological therapies targeting calcitonin gene-related peptide (CGRP), including monoclonal antibodies and gepants, have shown clinical effect and optimal tolerability. Interactions between treatments of Covid-19 and CGRP-related drugs have not been reviewed.
An overview of CGRP, a description of the characteristics of each CGRP-related drug and its response predictors, Covid-19 and its treatment, the interactions between CGRP-related drugs and Covid-19 treatment, Covid-19 and vaccination-induced headache, and the neurological consequences of Covid-19.
Clinicians should be careful about using gepants for Covid-19 patients, due to the potential drug interactions with drugs metabolized via CYP3A4 cytochrome. In particular, Covid-19 treatment (especially nirmatrelvir packaged with ritonavir, as Paxlovid) should be considered cautiously. It is advisable to stop or adjust the dose (10 mg atogepant when used for episodic migraine) of gepants when using Paxlovid (except for zavegepant). CGRP moncolconal antibodies (CGRP-mAbs) do not have drug – drug interactions, but a few days’ interval between a Covid-19 vaccination and the use of CGRP mAbs is recommended to allow the accurate identification of the possible adverse effects, such as injection site reaction. Covid-19- and vaccination-related headache are known to occur. Whether CGRP-related drugs would be of benefit in these circumstances is not yet known.